Home2020/06 June 30, 2020 -

https://mysicklefamilyllc.com/wp-content/uploads/2020/06/shutterstock_216367258-II-1280x720.jpg

Global Blood Therapeutics (GBT) plans to submit a marketing authorization application to the European Medicines Agency (EMA) asking that Oxbryta (voxelotor) be approved for treating hemolytic anemia in people with sickle cell disease (SCD) who are 12 or older. The submission is anticipated by mid-2021. GBT also is planning to start an early access program to give patients and clinicians access to Oxbryta prior to potential marketing authorization. “Currently, there are no approved therapies in...